Literature DB >> 21809066

[Influenza : clinical symptoms, diagnostics and therapy].

G G U Rohde1.   

Abstract

Influenza infections have important socio-economic consequences. Risk groups identified so far include small children and elderly adults with comorbidities. In recent years in addition to seasonal influenza an outbreak of avian influenza occurred in 2005 and the new H1N1 pandemic occurred in 2009. For the latter other at risk groups were affected and a different clinical course has been documented. The focus of this article is to give an overview on the epidemiology, clinical characteristics, diagnosis and therapy of influenza infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21809066     DOI: 10.1007/s00108-011-2859-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  61 in total

Review 1.  [Detection of respiratory viruses--how, when, where and why?].

Authors:  G Rohde; C Drosten; I Borg; B Hauptmeier; F Ringshausen; G Schultze-Werninghaus; K Uberla
Journal:  Pneumologie       Date:  2009-01-09

2.  Oral oseltamivir treatment of influenza in children.

Authors:  R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

3.  Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

Authors:  J A Hedrick; A Barzilai; U Behre; F W Henderson; J Hammond; L Reilly; O Keene
Journal:  Pediatr Infect Dis J       Date:  2000-05       Impact factor: 2.129

4.  Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010.

Authors:  Tiffany G Sheu; Alicia M Fry; Rebecca J Garten; Varough M Deyde; Thein Shwe; Lesley Bullion; Patrick J Peebles; Yan Li; Alexander I Klimov; Larisa V Gubareva
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

5.  Clinical evaluation of rapid point-of-care testing for detection of novel influenza A (H1N1) virus in a population-based study in Spain.

Authors:  V Ortiz de la Tabla; P Antequera; M Masiá; P Ros; C Martin; G Gazquez; F Buñuel; V Sánchez; C Robledano; F Gutiérrez
Journal:  Clin Microbiol Infect       Date:  2010-02-16       Impact factor: 8.067

Review 6.  Systematic review of influenza resistance to the neuraminidase inhibitors.

Authors:  Kristian Thorlund; Tahany Awad; Guy Boivin; Lehana Thabane
Journal:  BMC Infect Dis       Date:  2011-05-19       Impact factor: 3.090

7.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

8.  Surveillance activities and molecular analysis of H5N1 highly pathogenic avian influenza viruses from Thailand, 2004-2005.

Authors:  Chantanee Buranathai; Alongkorn Amonsin; Arunee Chaisigh; Apiradee Theamboonlers; Nuananong Pariyothorn; Yong Poovorawan
Journal:  Avian Dis       Date:  2007-03       Impact factor: 1.577

Review 9.  Antiviral therapy for influenza : a clinical and economic comparative review.

Authors:  Alexander C Schmidt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Authors:  Margaret Okomo-Adhiambo; Ha T Nguyen; Katrina Sleeman; Tiffany G Sheu; Varough M Deyde; Rebecca J Garten; Xiyan Xu; Michael W Shaw; Alexander I Klimov; Larisa V Gubareva
Journal:  Antiviral Res       Date:  2009-11-13       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.